Allergic Rhinoconjunctivitis Clinical Trial
Official title:
A Pilot Study Evaluating the Signs and Symptoms of Seasonal Allergic Rhinitis and Conjunctivitis Following Allergen Exposure in the Allergen BioCube
The objective of this study is to evaluate ocular and nasal signs and symptoms in patients with seasonal allergic rhinoconjunctivitis following allergen exposure in the Allergen BioCube.
n/a
Observational Model: Case-Only, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03850626 -
Validation of Combined Symptom Medication Score (cSMS) in Allergic Patients
|
||
Completed |
NCT03682965 -
Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study
|
Phase 2 | |
Completed |
NCT04541004 -
Adolescent Mite Allergy Safety Evaluation
|
Phase 3 | |
Completed |
NCT02556801 -
Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy
|
Phase 2 | |
Completed |
NCT01966224 -
A Safety and Immunogenicity Phase IB Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid Assessing the Long Term Safety of Previously Treated Subjects
|
Phase 1 | |
Completed |
NCT01918956 -
PURETHAL Birch RUSH Study
|
Phase 4 | |
Completed |
NCT01682070 -
SUBLIVAC FIX Phleum Pratense DT/DRF
|
Phase 2 | |
Completed |
NCT01438463 -
PURETHAL® Mites Dose Range Finding Study in Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis
|
Phase 2 | |
Completed |
NCT01438827 -
Avanz Phleum Pratense Maintenance Dose
|
Phase 2/Phase 3 | |
Completed |
NCT02437786 -
Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX®
|
Phase 4 | |
Completed |
NCT00985296 -
Conjunctival Allergen Challenge (CAC) Following Allergen Exposure in the Allergen BioCube (ABC)
|
N/A | |
Completed |
NCT01740284 -
A Trial Evaluating Tolerability of Grazax Treatment in Combination With Antihistamine
|
Phase 3 | |
Completed |
NCT04912076 -
S.C. Immunotherapy With BM41 in Patients With Allergic Rhino-conjunctivitis Caused by Birch Pollen
|
Phase 1 | |
Completed |
NCT03365648 -
Efficacy and Safety of Lertal® as an add-on to Standard Therapy for Allergic Rhinoconjunctivitis in Pediatrics
|
N/A | |
Completed |
NCT05455749 -
Effect of holoBLG on Cat Allergic Patients
|
N/A | |
Completed |
NCT01707069 -
A Safety and Immunogenicity Phase I Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid
|
Phase 1 | |
Completed |
NCT01466465 -
Vitamin D and Grass Pollen Specific Immunotherapy
|
Phase 2 | |
Completed |
NCT01567306 -
Phase II Trial With Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense
|
Phase 2 | |
Completed |
NCT01490411 -
Dose Range Finding Study With rBet v1-FV - in Adult Patients With Birch Pollen-Allergic Seasonal Rhinoconjunctivitis
|
Phase 2 | |
Completed |
NCT00777374 -
Study of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects With Epicutanoeus Allergen Administration
|
Phase 2 |